#eylea hashtag - Bluesky

3 days ago

Eylea Patient Tips: 7 things you should know Easy-to-read patient tips for Eylea covering how it works, benefits, risks, and best practices.

#Eylea and Eylea HD contain aflibercept, a VEGF inhibitor injected into the eye to treat wet macular degeneration, diabetic retinopathy, and related retinal conditions. The eye is numbed beforehand. Common side effects include temporary bleeding, eye pain, and redness.

0 0 0 0

Drugs.com

@drugs.com

7 months ago

Does Eylea have a biosimilar? Official answer: Yes, Eylea has five biosimilars: two that are designated as interchangeable (Opuviz and Yesafili) and three that are...

#Eylea has 5 biosimilars: Opuviz and Yesafili are interchangeable (pharmacist can substitute automatically), while Ahzantive, Enzeevu, and Pavblu require doctor approval. Interchangeable biosimilars can be safely switched back and forth.

0 0 0 0

Profit Trading USA

@profittradingusa.bsky.social

7 months ago

Rothschild bullish on Regeneron as pipeline strength outweighs Eylea decline Investing.com -- Rothschild initiated coverage of Regeneron Pharmaceuticals with a Buy rating and a $890 price target, saying the drugmaker’s pipeline potential is being overlooked amid concerns over its key eye drug Eylea. The bank said investor sentiment toward biotechnology has been weak, with the sector underperforming the S&P 500 since 2016 and funding conditions remaining tight. But it noted the industry has rebounded from past downturns, including a decade-long slump after the early 2000s tech bubble burst. Regeneron’s shares have dropped sharply since peaking in August 2024, hurt by slowing Eylea sales due to competition from Roche’s Vabysmo, limited uptake of its high-dose version, and the pending arrival of biosimilars. Sales and earnings forecasts for 2025 have been cut by 13% and 30% respectively. The stock also fell 19% in May after mixed data from its chronic obstructive pulmonary disease drug itepekimab. Rothschild called the sell-off overdone, arguing that investors are focusing too heavily on Eylea’s weakness while overlooking the breadth of the company’s development pipeline. The bank identified 15 experimental drugs it expects could each add at least $500 million in annual sales by 2031, with seven potentially generating $1–2 billion. It said the market’s tendency to assign no value to unapproved drugs, even on a probability-adjusted basis, understates Regeneron’s prospects. “Despite recent setbacks, this is about the pipeline more than the marketed portfolio,” Rothschild wrote, echoing comments from Regeneron’s chief executive earlier this year.

Click Subscribe #Rothschild #Regeneron #Eylea #pharmaceuticals #biotech

0 0 0 0

40:40 Recruitment - celia@4040recruitment.co.uk

@4040rec.bsky.social

8 months ago

Boehringer raises hope of oral drug for diabetic eye disease Boehringer has started a phase 2 trial of an oral therapy that could help people with diabetic macular oedema avoid regular injections into the eye.

#Ophthalmology #BoehringerIngelheim #diabeticeyedisease #diabeticmacularoedema #DME #BI1815368 #THULITEstudy #centreinvolvedDME #VEGFtargetingdrugs #Roche #Vabysmo #faricimab #Lucentis #ranibizumab #Bayer #Regeneron #Eylea #aflibercept #Susvimo #ranibizumab
pharmaphorum.com/news/boehrin...

0 0 0 0

@pharmalot.bsky.social

8 months ago

How Regeneron, maker of a best-selling eye drug, is using patent tactics to try to thwart competition A court battle between two of the nation’s largest biotechs is testing the legal limits of how far drugmakers can go in using patents to thwart competition.

“Only in the U.S. do we allow this game, this procedural tool," says Sean Tu, a University of Alabama law school professor who studies pharmaceutical patent issues.. "...It's a dumb system.”
statnews.com/pharmalot/20... #pharma #biotech #patents #eylea #Regeneron #Amgen

0 0 0 0

Simon J. Clark

@prof-clark.bsky.social

8 months ago

EU okays extended treatment interval for Bayer, Regeneron's higher-dose Eylea Bayer gained approval in the EU for an extended treatment interval of its higher-dose version of Eylea (aflibercept), something that was ...

EU okays extended treatment interval for Bayer, Regeneron's higher-dose Eylea buff.ly/4Yn1bT6

This will move the goalposts for assets whose USP is less frequent dosing. How much better are they going to have to be now? Once a year? #wetAMD #antiVEGF #eylea

0 0 0 0

pharmaphorum

@pharmaphorum.bsky.social

9 months ago

After FDA says no, Bayer bags EU nod for twice-yearly Eylea Bayer has been given a leg up in the competitive market for VEGF therapies used to treat eye diseases with a new EU approval for Eylea 8mg.

#Bayer has been given a leg up in the competitive market for #VEGF therapies used to treat eye diseases like wet age-related macular degeneration (#AMD) with a new approval for #Eylea 8mg.

pharmaphorum.com/news/after-f...

0 0 0 0

Profit Trading USA

@profittradingusa.bsky.social

10 months ago

Bayer secures EU nod for 6 month Eylea treatment, shares rise Investing,com -- Bayer (OTC:BAYRY) shares rose over 2% on Friday after the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended a label extension for Eylea 8 mg, allowing for longer treatment intervals for patients with two major retinal diseases. The CHMP opinion supports expanded dosing intervals of up to six months for aflibercept 8 mg, a treatment for neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME). The extension is contingent on a final decision from the European Commission, which is expected in the coming weeks. If approved, Eylea 8 mg would become the only anti-vascular endothelial growth factor (anti-VEGF) treatment in the EU authorized for six-month intervals for both nAMD and DME, according to Bayer’s statement Friday. “Following approval of the European Commission, extended treatment intervals with Eylea 8 mg of up to 6 months can significantly reduce the frequency of injections and visits to the clinic for patients,” said Christine Roth, executive vice president, Global Product Strategy and Commercialization at Bayer. The CHMP recommendation is based on three-year data from the PULSAR and PHOTON clinical trials. In these open-label extension studies, 24% of nAMD patients and 28% of DME patients who started with Eylea 8 mg at baseline were on six-month treatment intervals by the end of year three. Eylea 8 mg maintained the patients’ vision and anatomic outcomes over the study period, Bayer said. The safety profile remained consistent with that of the already-approved 2 mg dose, with no new safety signals reported. Eylea 8 mg is already approved in more than 50 markets, and further regulatory submissions are under review in additional countries. In the EU and U.K., Eylea 8 mg is the only anti-VEGF treatment currently approved for up to five-month intervals after three initial monthly injections.

Click Subscribe #Bayer #Eylea #Pharmaceuticals #EUApproval #Healthcare

0 0 0 0

Profit Trading USA

@profittradingusa.bsky.social

11 months ago